<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2307411-B1" country="EP" doc-number="2307411" kind="B1" date="20140101" family-id="41203949" file-reference-id="315036" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146553654" ucid="EP-2307411-B1"><document-id><country>EP</country><doc-number>2307411</doc-number><kind>B1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-09767698-A" is-representative="NO"><document-id mxw-id="PAPP154827577" load-source="docdb" format="epo"><country>EP</country><doc-number>09767698</doc-number><kind>A</kind><date>20090618</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140447894" ucid="US-2009047728-W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2009047728</doc-number><kind>W</kind><date>20090618</date></document-id></priority-claim><priority-claim mxw-id="PPC140446966" ucid="US-7420108-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>7420108</doc-number><kind>P</kind><date>20080620</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130711</date></intention-to-grant-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1988100468" load-source="ipcr">A61P  29/00        20060101ALI20100112BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988103840" load-source="ipcr">C07D 471/04        20060101AFI20100112BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988125170" load-source="ipcr">A61P  19/00        20060101ALI20100112BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988130846" load-source="ipcr">A61P   3/00        20060101ALI20100112BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988135026" load-source="ipcr">A61K  31/437       20060101ALI20100112BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1988105479" load-source="docdb" scheme="CPC">C07D 471/04        20130101 FI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132193446" lang="DE" load-source="patent-office">ALS KINASEINHIBITOREN GEEIGNETE TRIAZOLOPYRIDINVERBINDUNGEN</invention-title><invention-title mxw-id="PT132193447" lang="EN" load-source="patent-office">TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS</invention-title><invention-title mxw-id="PT132193448" lang="FR" load-source="patent-office">COMPOSÉS DE TRIAZOLOPYRIDINE UTILISÉS COMME INHIBITEURS DE KINASE</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR918151204" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>SQUIBB BRISTOL MYERS CO</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR918170795" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>BRISTOL-MYERS SQUIBB COMPANY</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918160542" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>HYNES JOHN</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918140687" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>HYNES, JOHN</last-name></addressbook></inventor><inventor mxw-id="PPAR918997456" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>HYNES, JOHN</last-name><address><street>Bristol-Myers Squibb Co., Route 206 &amp; Province Line Road</street><city>Princeton, NJ 08543</city><country>US</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR918997458" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Bristol-Myers Squibb Company</last-name><iid>101086875</iid><address><street>Route 206 and Province Line Road</street><city>Princeton, NJ 08543-4000</city><country>US</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR918997457" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Beacham, Annabel Rose</last-name><iid>100044107</iid><address><street>Dehns St Bride's House 10 Salisbury Square</street><city>London EC4Y 8JD</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2009047728-W"><document-id><country>US</country><doc-number>2009047728</doc-number><kind>W</kind><date>20090618</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2009155389-A1"><document-id><country>WO</country><doc-number>2009155389</doc-number><kind>A1</kind><date>20091223</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS548981565" load-source="docdb">AT</country><country mxw-id="DS548977905" load-source="docdb">BE</country><country mxw-id="DS548865168" load-source="docdb">BG</country><country mxw-id="DS548979360" load-source="docdb">CH</country><country mxw-id="DS548829507" load-source="docdb">CY</country><country mxw-id="DS548829508" load-source="docdb">CZ</country><country mxw-id="DS548980233" load-source="docdb">DE</country><country mxw-id="DS548977910" load-source="docdb">DK</country><country mxw-id="DS548977911" load-source="docdb">EE</country><country mxw-id="DS548884626" load-source="docdb">ES</country><country mxw-id="DS548865169" load-source="docdb">FI</country><country mxw-id="DS548865170" load-source="docdb">FR</country><country mxw-id="DS548980234" load-source="docdb">GB</country><country mxw-id="DS548977912" load-source="docdb">GR</country><country mxw-id="DS548980235" load-source="docdb">HR</country><country mxw-id="DS548829509" load-source="docdb">HU</country><country mxw-id="DS548979361" load-source="docdb">IE</country><country mxw-id="DS548977913" load-source="docdb">IS</country><country mxw-id="DS548865171" load-source="docdb">IT</country><country mxw-id="DS548977918" load-source="docdb">LI</country><country mxw-id="DS548980236" load-source="docdb">LT</country><country mxw-id="DS548981570" load-source="docdb">LU</country><country mxw-id="DS548865172" load-source="docdb">LV</country><country mxw-id="DS548980237" load-source="docdb">MC</country><country mxw-id="DS548981571" load-source="docdb">MK</country><country mxw-id="DS548981572" load-source="docdb">MT</country><country mxw-id="DS548865173" load-source="docdb">NL</country><country mxw-id="DS548979362" load-source="docdb">NO</country><country mxw-id="DS548865174" load-source="docdb">PL</country><country mxw-id="DS548884627" load-source="docdb">PT</country><country mxw-id="DS548980238" load-source="docdb">RO</country><country mxw-id="DS548865175" load-source="docdb">SE</country><country mxw-id="DS548988750" load-source="docdb">SI</country><country mxw-id="DS548979363" load-source="docdb">SK</country><country mxw-id="DS548977919" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63957328" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001">FIELD OF THE INVENTION</heading><p id="p0001" num="0001">This invention relates to triazolopyridine compounds useful for treating p38 kinase-associated conditions. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating kinase-associated conditions, such as p38 kinase-associated conditions.</p><heading id="h0002">BACKGROUND OF THE INVENTION</heading><p id="p0002" num="0002">A large number of cytokines participate in the inflammatory response, including IL-1, IL-6, IL-8 and TNF-α. Overproduction of cytokines such as IL-1 and TNF-α are implicated in a wide variety of diseases, including inflammatory bowel disease, rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease, and congestive heart failure, among others [<nplcit id="ncit0001" npl-type="s"><text>Henry et al., Drugs Fut., 24:1345-1354 (1999</text></nplcit>); <nplcit id="ncit0002" npl-type="s"><text>Salituro et al., Curr. Med. Chem., 6:807-823 (1999</text></nplcit>)]. Evidence in human patients indicates that protein antagonists of cytokines are effective in treating chronic inflammatory diseases, such as, for example, monoclonal antibody to TNF-α (Enbrel) [<nplcit id="ncit0003" npl-type="s"><text>Rankin et al., Br. J. Rheumatol., 34:334-342 (1995</text></nplcit>)], and soluble TNF-α receptor-Fc fusion protein (Etanercept) [<nplcit id="ncit0004" npl-type="s"><text>Moreland et al., Ann. Intern. Med., 130:478-486 (1999</text></nplcit>)].</p><p id="p0003" num="0003">The biosynthesis of TNF-α occurs in many cell types in response to an external stimulus, such as, for example, a mitogen, an infectious organism, or trauma. Important mediators of TNF-α production are the mitogen-activated protein (MAP) kinases. These kinases are activated in response to various stress stimuli, including, but not limited to, proinflammatory cytokines, endotoxin, ultraviolet light, and osmotic shock.<!-- EPO <DP n="2"> --></p><p id="p0004" num="0004">One important MAP kinase is p38 kinase, also known as cytokine suppressive anti-inflammatory drug binding protein (CSBP) or IK. Activation of p38 requires dual phosphorylation by upstream MAP kinase kinases (MKK3 and MKK6) on threonine and tyrosine within a Thr-Gly-Tyr motif characteristic of p38 isozymes. There are four known isoforms of p38, <i>i.e</i>., p38α, p38β, p38γ, and p38δ. The α and β isoforms are expressed in inflammatory cells and are key mediators of TNF-α production. Inhibiting the p38α and β enzymes in cells results in reduced levels of TNF-α expression. Also, administering p38α and β inhibitors in animal models of inflammatory disease has proven that such inhibitors are effective in treating those diseases. Accordingly, the p38 enzymes serve an important role in inflammatory processes mediated by IL-1 and TNF-α.</p><p id="p0005" num="0005">Compounds that reportedly inhibit p38 kinase and cytokines, such as IL-1 and TNF-α for use in treating inflammatory diseases, are disclosed in <patcit id="pcit0001" dnum="US6277989B"><text>U.S. Patent Nos. 6,277,989</text></patcit> and <patcit id="pcit0002" dnum="US6130235B"><text>6,130,235</text></patcit> to Scios, Inc; <patcit id="pcit0003" dnum="US6147080A"><text>U.S. Patent Nos. 6,147,080</text></patcit> and <patcit id="pcit0004" dnum="US5945418A"><text>5,945,418</text></patcit> to Vertex Pharmaceuticals Inc; <patcit id="pcit0005" dnum="US6251914B"><text>U.S. Patent Nos. 6,251,914,</text></patcit> <patcit id="pcit0006" dnum="US5977103A"><text>5,977,103 </text></patcit>and <patcit id="pcit0007" dnum="US5658903A"><text>5,658,903</text></patcit> to Smith-Kline Beecham Corp.; <patcit id="pcit0008" dnum="US5932576A"><text>U.S. Patent Nos. 5,932,576</text></patcit> and <patcit id="pcit0009" dnum="US6087496A"><text>6,087,496</text></patcit> to G.D. Searle &amp; Co.; <patcit id="pcit0010" dnum="WO0056738A"><text>PCT publication numbers WO 00/56738</text></patcit> and <patcit id="pcit0011" dnum="WO0127089A"><text>WO 01/27089</text></patcit> to Astra Zeneca; <patcit id="pcit0012" dnum="WO0134605A"><text>WO 01/34605</text></patcit> to Johnson &amp; Johnson; <patcit id="pcit0013" dnum="WO0012497A"><text>WO 00/12497</text></patcit> (quinazoline derivatives as p38 kinase inhibitors); <patcit id="pcit0014" dnum="WO0056738A"><text>WO 00/56738</text></patcit> (pyridine and pyrimidine derivatives for the same purpose); <patcit id="pcit0015" dnum="WO0012497A"><text>WO 00/12497</text></patcit> (discusses the relationship between p38 kinase inhibitors); <patcit id="pcit0016" dnum="WO0012074A"><text>WO 00/12074</text></patcit> (piperazine and piperidine compounds useful as p38 inhibitors); and <patcit id="pcit0017" dnum="EP1247810A"><text>EP 1247810</text></patcit> (benzotriazoles useful as p38 inhibitors).</p><p id="p0006" num="0006">The present invention provides certain triazolopyridine compounds useful as kinase inhibitors, particularly p38 kinases.</p><heading id="h0003">SUMMARY OF THE INVENTION</heading><p id="p0007" num="0007">The instant invention generally pertains to compounds of Formula I,
<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="38" he="34" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="3"> -->
and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof (particularly pharmaceutically-acceptable salts), wherein:
<ul><li>R<sup>1</sup> is thiazol-5-yl substituted at the 2 position with C<sub>1-6</sub> alkyl amino; and</li><li>R<sup>2</sup> is phenyl optionally substituted with one or more substituents selected from the group consisting of halo, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl and hydroxy.</li></ul></p><p id="p0008" num="0008">Listed below are definitions of various terms used to describe this invention. These definitions apply to the terms as they are used throughout this specification, unless otherwise limited in specific instances, either individually or as part of a larger group.</p><p id="p0009" num="0009">The terms "alkyl" and "alk" refer to a straight or branched chain alkane (hydrocarbon) radical containing from 1 to 6 carbon atoms. Exemplary groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl and isohexyl. The term "lower alkyl" is used herein to refer to those alkyl groups having from 1 to 6 carbon atoms and, more particularly, 1-4.<!-- EPO <DP n="4"> --></p><p id="p0010" num="0010">The term "halo" refers to chlorine, bromine, fluorine or iodine.</p><p id="p0011" num="0011">When it is stated that a group may be "optionally substituted," this is intended to include unsubstituted groups and substituted groups wherein the substituents are selected from those recited for the particularly named group. Thus, when reference is made to an optionally substituted aryl, it is intended to refer to unsubstituted aryl groups, such as phenyl or naphthyl, and such groups having one or more (preferably 1 to 4, and more preferably 1 or 2) substituents.<!-- EPO <DP n="5"> --></p><p id="p0012" num="0012">"Solvate" refers to a molecular or ionic complex of molecules or ions of solvent with molecules or ions of solute. It should further be understood that solvates (<i>e.g.,</i> hydrates) of the compounds of Formula I are also within the scope of the present invention. Methods of solvation are generally known in the art.</p><p id="p0013" num="0013">When a functional group is termed "protected", this means that the group is in modified form to mitigate, especially preclude, undesired side reactions at the protected site. Suitable protecting groups for the methods and compounds described herein include, without limitation, those described in standard textbooks, such as <nplcit id="ncit0005" npl-type="b"><text>Greene, T. W. et al., Protective Groups in Organic Synthesis, Wiley, N.Y. (1991</text></nplcit>).</p><p id="p0014" num="0014">Unless otherwise indicated, any carbon atom or heteroatom with unsatisfied valences is assumed to have hydrogen atoms sufficient to satisfy the valences.</p><p id="p0015" num="0015">Carboxylate anion refers to a negatively charged group -COO<sup>-</sup>.</p><p id="p0016" num="0016">The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include <sup>13</sup>C and <sup>14</sup>C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by<!-- EPO <DP n="6"> --> processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds have a variety of potential uses, <i>e.g</i>., as standards and reagents in determining the ability of a potential pharmaceutical compound to bind to target proteins or receptors, or for imaging compounds of this invention bound to biological receptors <i>in vivo</i> or <i>in vitro.</i></p><p id="p0017" num="0017">The compounds of the present invention may form salts which are also within the scope of this invention. Pharmaceutically acceptable (<i>i</i>.<i>e</i>., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful, <i>e.g</i>., in isolating or purifying the compounds of this invention.</p><p id="p0018" num="0018">The compounds of the present invention may form salts with alkali metals such as sodium, potassium, and lithium; with alkaline earth metals such as calcium and magnesium; and with organic bases such as dicyclohexylamine, tributylamine, pyridine, and amino acids such as arginine, lysine, and the like. Such salts can be formed as known to those skilled in the art.</p><p id="p0019" num="0019">The compounds of the present invention may form salts with a variety of organic and inorganic acids. Such salts include those formed with hydrogen chloride, hydrogen bromide, methanesulfonic acid, sulfuric acid, acetic acid, trifluoroacetic acid, oxalic acid, maleic acid, benzenesulfonic acid, toluenesulfonic acid, and various others (<i>e.g</i>., nitrates, phosphates, borates, tartrates, citrates, succinates, benzoates, ascorbates, salicylates, and the like). Such salts can be formed as known to those skilled in the art. Salt forms of the compounds may be advantageous for improving the compound dissolution rate and oral bioavailability.</p><p id="p0020" num="0020">In addition, zwitterions ("inner salts") may be formed.</p><p id="p0021" num="0021">All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The definition of compounds according to the invention embraces all the possible stereoisomers and their mixtures; it also embraces the racemic forms and the isolated optical isomers having the specified activity. The racemic forms can be resolved by physical methods, such as, for example, fractional crystallization, separation, or crystallization of diastereomeric derivatives or separation by chiral column chromatography. The individual optical isomers can be obtained from the racemates<!-- EPO <DP n="7"> --> from the conventional methods, such as, for example, salt formation with an optically active acid followed by crystallization.</p><heading id="h0004">DETAILED DESCRIPTION OF THE INVENTION</heading><p id="p0022" num="0022">One embodiment of the present invention relates to a compound of Formula I
<chemistry id="chem0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="38" he="34" img-content="chem" img-format="tif"/></chemistry>
and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof, wherein:
<ul><li>R<sup>1</sup> is thiazol-5-yl substituted at the 2 position with C<sub>1-6</sub> alkyl amino; and</li><li>R<sup>2</sup> is phenyl optionally substituted with one or more substituents selected from the group consisting of halo, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl and hydroxy.</li></ul><!-- EPO <DP n="8"> --></p><p id="p0023" num="0023">More particular values of R<sup>1</sup> are found in the compounds set forth in the Examples, such as the compounds listed in Table 1. For example, R<sup>1</sup> may be selected from the group consisting of:
<chemistry id="chem0003" num="0003"><img id="ib0003" file="imgb0003.tif" wi="111" he="31" img-content="chem" img-format="tif"/></chemistry>
In another embodiment, the compound is selected from the group consisting of:
<chemistry id="chem0004" num="0004"><img id="ib0004" file="imgb0004.tif" wi="119" he="43" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0005" num="0005"><img id="ib0005" file="imgb0005.tif" wi="112" he="40" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0006" num="0006"><img id="ib0006" file="imgb0006.tif" wi="78" he="41" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="9"> -->
<chemistry id="chem0007" num="0007"><img id="ib0007" file="imgb0007.tif" wi="136" he="37" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0008" num="0008"><img id="ib0008" file="imgb0008.tif" wi="116" he="40" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0009" num="0009"><img id="ib0009" file="imgb0009.tif" wi="114" he="39" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="10"> --></p><p id="p0024" num="0024">In another embodiment, the instant invention is directed to a pharmaceutical composition comprising at least one compound according to Formula I (including all of the subgroups and particular groups described above) and a pharmaceutically-acceptable carrier or diluent.<!-- EPO <DP n="11"> --></p><p id="p0025" num="0025">In a more particular embodiment, the pharmaceutical composition is a solid dosage form.</p><p id="p0026" num="0026">Other embodiments of the present invention are 1) a compound of Formula 1 for use in therapy, and 2) a compound of Formula I for use in treating a disease or disorder, wherein the disease or disorder is an inflammatory disorder.</p><p id="p0027" num="0027">In a further embodiment, the aforementioned inflammatory disorder is selected from the group consisting of rheumatoid arthritis, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, multiple myeloma, multiple sclerosis, pain, myocardial ischemia and arthritis. More particularly, the disorder is selected from the group consisting of psoriasis, atherosclerosis, pain, and rheumatoid arthritis.</p><p id="p0028" num="0028">The invention may be embodied in other specific forms without departing from the essential attributes thereof. This invention also encompasses all combinations of alternative aspects and embodiments of the invention noted herein. It is understood that any and all embodiments may be taken in conjunction with any other embodiment to describe additional embodiments of the present invention. Furthermore, any elements of an embodiment are meant to be combined with any and all other elements from any of the embodiments to describe additional embodiments.</p><heading id="h0005">UTILITY</heading><p id="p0029" num="0029">The compounds of the invention are selective inhibitors of p38 kinase activity. Accordingly, compounds of Formula I have utility in treating conditions associated with p38 kinase activity. Such conditions include diseases in which cytokine levels are modulated as a consequence of intracellular signaling via p38, and<!-- EPO <DP n="12"> --> in particular, diseases that are associated with an overproduction of cytokines IL-1, IL-4, IL-8, and TNF-α. As used herein, the terms "treating" or "treatment" encompass either or both responsive and prophylaxis measures, <i>e.g</i>., measures designed to inhibit or delay the onset of the disease or disorder, achieve a full or partial reduction of the symptoms or disease state, and/or to alleviate, ameliorate, lessen, or cure the disease or disorder and/or its symptoms.</p><p id="p0030" num="0030">In view of their activity as inhibitors of p-38 kinase, compounds of Formula I are useful in treating p-38 associated conditions including, but not limited to, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, angiogenic disorders, infectious diseases, neurodegenerative diseases, and viral diseases.</p><p id="p0031" num="0031">More particularly, the specific conditions or diseases that may be treated with the inventive compounds include, without limitation, pancreatitis (acute or chronic), asthma, allergies, acute respiratory distress syndrome, chronic obstructive pulmonary disease, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosis, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, graft vs. host disease, inflammatory reaction induced by endotoxin, tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, pancreatic β-cell disease; diseases characterized by massive neutrophil infiltration; rheumatoid spondylitis, gouty arthritis and other arthritic conditions, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis, bone resorption disease, allograft rejections, fever and myalgias due to infection, cachexia secondary to infection, meloid formation, scar tissue formation, ulcerative colitis, pyresis, influenza, osteoporosis, osteoarthritis and multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, sepsis, septic shock, and Shigellosis; Alzheimer's disease, Parkinson's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury; angiogenic disorders including<!-- EPO <DP n="13"> --> solid tumors, ocular neovasculization, and infantile haemangiomas; viral diseases including acute hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), HIV infection and CMV retinitis, AIDS, ARC or malignancy, and herpes; stroke, myocardial ischemia, ischemia in stroke heart attacks, organ hyposia, vascular hyperplasia, cardiac and renal reperfusion injury, thrombosis, cardiac hypertrophy, thrombin-induced platelet aggregation, endotoxemia and/or toxic shock syndrome, and conditions associated with prostaglandin endoperoxidase syndase-2.</p><p id="p0032" num="0032">In addition, p38 inhibitors of this invention inhibit the expression of inducible pro-inflammatory proteins such as prostaglandin endoperoxide synthase-2 (PGHS-2), also referred to as cyclooxygenase-2 (COX-2). Accordingly, additional p38-associated conditions include edema, analgesia, fever and pain, such as neuromuscular pain, headache, pain caused by cancer, dental pain and arthritis pain. The inventive compounds also may be used to treat veterinary viral infections, such as lentivirus infections, including, but not limited to equine infectious anemia virus; or retro virus infections, including feline immunodeficiency virus, bovine immunodeficiency virus, and canine immunodeficiency virus.</p><p id="p0033" num="0033">When the terms "p38 associated condition" or "p38 associated disease or disorder" are used herein, each is intended to encompass all of the conditions identified above as if repeated at length, as well as any other condition that is affected by p38 kinase activity.</p><p id="p0034" num="0034">Particular examples of diseases that would benefit from p38 inhibitors are rheumatoid arthritis, asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, diabetes, inflammatory bowel disease, ulcerative colitis, Crohn's disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, acute coronary disease, multiple myeloma, multiple sclerosis, acute myelogenous leukemia, chronic myelogenous leukemia, pain, myocardial ischemia and arthritis including rheumatoid arthritis, psoriatic arthritis, traumatic arthritis, rubella arthritis, gouty arthritis and osteoarthritis. Even more particular examples include disorders selected from the group consisting of rheumatoid arthritis, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, multiple<!-- EPO <DP n="14"> --> myeloma, multiple sclerosis, pain, myocardial ischemia and arthritis, especially those disorders selected from the group consisting of psoriasis, atherosclerosis, pain, and rheumatoid arthritis.</p><p id="p0035" num="0035">The present invention thus provides compounds for use in methods for treating such conditions, comprising administering to a subject in need thereof an effective amount of at least one compound of Formula I or a salt thereof. The methods of treating p38 kinase-associated conditions may comprise administering compounds of Formula I alone or in combination with other suitable therapeutic agents useful in treating such conditions. Exemplary of such other therapeutic agents include corticosteroids, rolipram, calphostin, CSAIDs, 4-substituted imidazo [1,2-A]quinoxalines as disclosed in <patcit id="pcit0018" dnum="US4200750A"><text>US Pat. No. 4,200,750</text></patcit>; Interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; nuclear translocation inhibitors, such as deoxyspergualin (DSG); non-steroidal antiinflammatory drugs (NSAIDs) such as ibuprofen, celecoxib and rofecoxib; steroids such as prednisone or dexamethasone; antiviral agents such as abacavir; antiproliferative agents such as methotrexate, leflunomide, FK506 (tacrolimus, PROGRAF®); cytotoxic drugs such as azathiprine and cyclophosphamide; TNF-α inhibitors such as tenidap, anti-TNF antibodies or soluble TNF receptor, and rapamycin (sirolimus or RAPAMUNE®) or derivatives thereof.</p><p id="p0036" num="0036">The above other therapeutic agents, when employed in combination with the compounds of the present invention, may be used, for example, in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art. In the methods of the present invention, such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the inventive compounds.</p><p id="p0037" num="0037">The present invention also provides pharmaceutical compositions capable of treating p38-kinase associated conditions, including TNF-α, IL-1, and/or IL-8 mediated conditions, as described above. The inventive compositions may contain other therapeutic agents as described above and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (<i>e.g</i>., excipients,<!-- EPO <DP n="15"> --> binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.</p><p id="p0038" num="0038">The compounds of Formula I may be administered by any means suitable for the condition to be treated, which may depend on the need for site-specific treatment or quantity of drug to be delivered. Topical administration is generally preferred for skin-related diseases, and systematic treatment preferred for cancerous or pre-cancerous conditions, although other modes of delivery are contemplated. For example, the compounds may be delivered orally, such as in the form of tablets, capsules, granules, powders, or liquid formulations including syrups; topically, such as in the form of solutions, suspensions, gels or ointments; sublingually; bucally; parenterally, such as by subcutaneous, intravenous, intramuscular or intrastemal injection or infusion techniques (<i>e.g</i>., as sterile injectable aq. or non-aq. solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; rectally such as in the form of suppositories; or liposomally. Dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents may be administered. The compounds may be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved with suitable pharmaceutical compositions or, particularly in the case of extended release, with devices such as subcutaneous implants or osmotic pumps.</p><p id="p0039" num="0039">Exemplary compositions for topical administration include a topical carrier such as Plastibase (mineral oil gelled with polyethylene).</p><p id="p0040" num="0040">Exemplary compositions for oral administration include suspensions which may contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which may contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. The inventive compounds may also be orally delivered by sublingual and/or buccal administration, <i>e.g</i>., with molded, compressed, or freeze-dried tablets. Exemplary compositions may include fast-dissolving diluents such as<!-- EPO <DP n="16"> --> mannitol, lactose, sucrose, and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (AVICEL®) or polyethylene glycols (PEG); an excipient to aid mucosal adhesion such as hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl cellulose (SCMC), and/or maleic anhydride copolymer (<i>e.g</i>., Gantrez); and agents to control release such as polyacrylic copolymer (<i>e.g</i>., Carbopol 934). Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.</p><p id="p0041" num="0041">Exemplary compositions for nasal aerosol or inhalation administration include solutions which may contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance absorption and/or bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.</p><p id="p0042" num="0042">Exemplary compositions for parenteral administration include injectable solutions or suspensions which may contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.</p><p id="p0043" num="0043">Exemplary compositions for rectal administration include suppositories which may contain, for example, suitable non-irritating excipients, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures but liquefy and/or dissolve in the rectal cavity to release the drug.</p><p id="p0044" num="0044">The effective amount of a compound of the present invention may be determined by one of ordinary skill in the art, and includes exemplary dosage amounts for a mammal of from about 0.05 to 100 mg/kg of body weight of active compound per day, which may be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day. It will be understood that the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors, including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the<!-- EPO <DP n="17"> --> particular condition. Preferred subjects for treatment include animals, most preferably mammalian species such as humans, and domestic animals such as dogs, cats, horses, and the like. Thus, when the term "patient" is used herein, this term is intended to include all subjects, most preferably mammalian species, that are affected by mediation of p38 enzyme levels.</p><p id="p0045" num="0045">Compounds described in the examples <i>infra</i>, have been tested in one or more of the assays described below and have shown activity as inhibitors of p38 enzymes.</p><heading id="h0006">BIOLOGICAL ASSAYS</heading><heading id="h0007">Generation of p38 Kinases</heading><p id="p0046" num="0046">For this assay, cDNAs of human p38α, β, and γ isozymes were cloned by PCR. These cDNAs were subcloned in the pGEX expression vector (Pharmacia). GST-p38 fusion protein was expressed in E. Coli and purified from bacterial pellets by affinity chromatography using glutathione agarose. p38 fusion protein was activated by incubating with constitutively active MKK6. Active p38 was separated from MKK6 by affinity chromatography. Constitutively active MKK6 was generated according to <nplcit id="ncit0006" npl-type="s"><text>Raingeaud et al. (Mol. Cell. Biol., 1247-1255 (1996</text></nplcit>)).</p><heading id="h0008">p38 Assay</heading><p id="p0047" num="0047">The assays were performed in V-bottomed 96-well plates. The final assay volume was 60 µl prepared from three 20 µl additions of enzyme, substrates (MBP and ATP) and test compounds in assay buffer (50 mM Tris pH 7.5, 10 mM MgCl<sub>2</sub>, 50 mM NaCl and 1 mM DTT). Bacterially expressed, activated p38 was pre-incubated with test compounds for 10 min. prior to initiation of reaction with substrates. The reaction was incubated at 25°C for 45 min. and terminated by adding 5 µl of 0.5 M EDTA to each sample. The reaction mixture was aspirated onto a pre-wet filtermat using a SKATRON® Micro96 Cell Harvester (Skatron, Inc.), then washed with PBS. The filtermat was then dried in a microwave oven for 1 min., treated with MELTILEX® A scintillation wax (Wallac), and counted on a MICROBETA® scintillation counter Model 1450 (Wallac). Inhibition data were analyzed by nonlinear least-squares regression using PRIZM® (GraphPadSoftware). The final<!-- EPO <DP n="18"> --> concentration of reagents in the assays are ATP, 1 µM; [γ-<sup>33</sup>P]ATP, 3 nM,; MBP (Sigma, #M1891), 2µg/well; p38, 10 nM; and DMSO, 0.3%.</p><heading id="h0009">METHODS OF PREPARATION</heading><p id="p0048" num="0048">The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.</p><p id="p0049" num="0049">The novel compounds of this invention may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and work up procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents that are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is <nplcit id="ncit0007" npl-type="b"><text>Greene, T.W. et al. (Protective Groups in Organic Synthesis, Third Edition, Wiley and Sons (1999</text></nplcit>)).<!-- EPO <DP n="19"> --> ABBREVIATIONS</p><p id="p0050" num="0050">For ease of reference, the following abbreviations are employed herein, including the methods of preparation and Examples that follow:
<ul><li>Ph = phenyl</li><li>Bz = benzyl</li><li>t-Bu = tertiary butyl</li><li>Me = methyl</li><li>Et = ethyl</li><li>Pr = propyl</li><li>Iso-P = isopropyl</li><li>MeOH = methanol</li><li>EtOH = ethanol</li><li>EtOAc = ethyl acetate</li><li>Boc = <i>tert</i>-butyloxycarbonyl</li><li>CBZ = carbobenzyloxy or carbobenzoxy or benzyloxycarbonyl</li><li>DMF = dimethyl formamide</li><li>DMSO = dimethyl sulfoxide</li><li>TFA = trifluoroacetic acid</li><li>THF = tetrahydrofuran</li><li>KOH = potassium hydroxide</li><li>K<sub>2</sub>CO<sub>3</sub> = potassium carbonate</li><li>POCl<sub>3</sub> =phosphorous oxychloride</li><li>KOtBu = potassium <i>t</i>-butoxide</li><li>EDC or EDCI = 3-ethyl-3'-(dimethylamino)propyl-carbodiimide</li><li>DIPEA = diisopropylethylamine</li><li>HOBt= 1-hydroxybenzotriazole hydrate</li><li>NaH = sodium hydride</li><li>NaOH = sodium hydroxide</li><li>Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> = sodium thiosulfate</li><li>Pd = palladium</li><li>min = minute(s)</li><li>L = liter<!-- EPO <DP n="20"> --></li><li>mL = milliliter</li><li>µL = microliter</li><li>g = gram(s)</li><li>mg = milligram(s)</li><li>mol = moles</li><li>mmol = millimole(s)</li><li>meq = milliequivalent</li><li>RT = room temperature</li><li>RBF = round bottom flask</li><li>ret. t. = HPLC retention time (minutes)</li><li>sat or sat'd = saturated</li><li>aq. = aqueous</li><li>TLC = thin layer chromatography</li><li>HPLC = high performance liquid chromatography</li><li>LC/MS = high performance liquid chromatography/mass spectrometry</li><li>MS = mass spectrometry</li><li>NMR = nuclear magnetic resonance</li><li>mp = melting point</li></ul></p><p id="p0051" num="0051">Generally, as shown in Reference Scheme 1, p38 inhibitors of the formula (<b>I.1</b>) can be prepared from the substituted pyridinone <b>1.1</b> which can be prepared according methods described in the literature. Pyridinone <b>1.1</b> can be derivatized to the chloride <b>1.2</b> with, for example, POCL<sub>3</sub> then reacted with hydrazine to form intermediate <b>1.3.</b> Pyridine <b>1.3</b> can be cyclized with trimethylorthoformate in the presence of acid to form the fused 6,5-traizolopyridine intermediate <b>1.4.</b> Reaction with a variety of cross coupling reagents, such as an aryl boronic acid, followed by hydrolysis of the pendant ester can provide the intermediate <b>1.5.</b> Reaction of <b>1.5</b> with a derivatizing reagent, such as DPPA, followed by heating in the presence of a nucleophile can provide compounds of the general formula (<b>I.1</b>).<!-- EPO <DP n="21"> -->
<chemistry id="chem0010" num="0010"><img id="ib0010" file="imgb0010.tif" wi="147" he="100" img-content="chem" img-format="tif"/></chemistry></p><p id="p0052" num="0052">Schemes 2 and 3 illustrate alternative methods for preparing compounds of the general invention. However, it will become evident to one of ordinary skill in the art that Schemes 2 and 3 represent only 2 specific subsets of routes and it would be possible to modify the illustrated routes to prepare additional compounds of the general formula (I). For example, the commercially available boronic acid <b>2.1</b> can be coupled to an aryl halide to give intermediate <b>2.2.</b> Displacement of the fluoro group with hydrazine can afford <b>2.3</b> which, in turn can be cyclized with an orthoformate in the presence of acid to give <b>2.4.</b> Coupling with a vinyl ether stannane, or an appropriate equivalent, can provide <b>2.5</b> which upon further reaction with NBS and a thiourea can afford compounds of the general structure <b>1.2a.</b> Alternatively, 2-ethoxythiazole can be converted to the stannane intermediate <b>2.7</b> and then reacted with an aryl bromide <b>2.4</b> to provide additional compounds of the formula <b>1.2b.</b><!-- EPO <DP n="22"> -->
<chemistry id="chem0011" num="0011"><img id="ib0011" file="imgb0011.tif" wi="146" he="151" img-content="chem" img-format="tif"/></chemistry></p><p id="p0053" num="0053">An alternative method of preparation is outlined in Scheme 3. A pyridyl aldehyde (<b>3.1</b>) can be brominated to intermediate <b>3.2</b> with bromine in acetic acid. Further reaction of the aldehyde with an olefinating reagent, such as (methoxymethyl)triphenylphosphonium chloride/KOtBu can afford the vinyl ether <b>3.3.</b> Treatment of this ether with NBS in water in the presence of a substituted thiourea, such as <b>3.4,</b> can afford the substituted Aminothiazole <b>3.5.</b> Hydrolysis can afford <b>3.6</b> which can be converted to the chloride <b>3.7</b> with POCl<sub>3</sub>. The intermediate <b>3.7</b> can be reacted with hydrazine to give the 2-hydrazino pyridine <b>3.8</b> which can be cyclized to give <b>3.9.</b> The bromide of <b>3.9</b> can be further reacted with a variety of cross coupling reagents to afford compounds of the general formula <b>I.3.</b><!-- EPO <DP n="23"> -->
<chemistry id="chem0012" num="0012"><img id="ib0012" file="imgb0012.tif" wi="144" he="112" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="24"> --></p><heading id="h0010">EXAMPLES</heading><p id="p0054" num="0054">The following Examples are offered as illustrative as a partial scope of the invention and are not meant to be limiting of the scope of the invention. Unless otherwise indicated, they have been prepared, isolated and characterized using the Schemes and other methods disclosed herein. The abbreviations used herein are defined above.</p><p id="p0055" num="0055">In the Examples, "HPLC Condition A" refers to YMC S5 ODS-A 4.6 x 50 mm column, 4 mL/min flow rate, 4 min linear gradient elution (Start solvent %B = 0; Final solvent %B = 100), solvent A = 10% MeOH / 90% H<sub>2</sub>O / 0.2% H<sub>3</sub>PO<sub>4</sub>; solvent B = 90% MeOH / 10% H<sub>2</sub>O / 0.2% H<sub>3</sub>PO<sub>4</sub>. "HPLC Condition B" refers to Chromolith Speedrod 4.6 x 50 mm column, 4 mL/min flow rate, 4 min linear gradient elution (Start solvent %B = 0; Final solvent %B = 100), solvent A = 10% MeOH / 90% H<sub>2</sub>O / 0.2% H<sub>3</sub>PO<sub>4</sub>; solvent B = 90% MeOH / 10% H<sub>2</sub>O / 0.2% H<sub>3</sub>PO<sub>4</sub>. "HPLC Condition C" refers to Waters Sunfire C184.6 x 50 mm column, 4 mL/min flow rate, 4 min linear gradient elution (Start solvent %B = 0; Final solvent %B = 100), solvent A = 10% MeOH / 90% H<sub>2</sub>O / 0.1 % TFA; solvent B = 90% MeOH / 10% H<sub>2</sub>O / 0.1 % TFA.<!-- EPO <DP n="25"> --></p><heading id="h0011">EXAMPLE 4</heading><heading id="h0012">5-(8-Phenyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-N-propylthiazol-2-amine</heading><p id="p0056" num="0056"><chemistry id="chem0013" num="0013"><img id="ib0013" file="imgb0013.tif" wi="43" he="44" img-content="chem" img-format="tif"/></chemistry></p><heading id="h0013">Step 1. Preparation of 5-bromo-2-fluoro-3-phenylpyridine</heading><p id="p0057" num="0057"><chemistry id="chem0014" num="0014"><img id="ib0014" file="imgb0014.tif" wi="23" he="28" img-content="chem" img-format="tif"/></chemistry></p><p id="p0058" num="0058">A solution of 5-bromo-2-fluoropyridin-3-ylboronic acid (620 mg, 2.82 mmol) and 1-iodobenzene (292 µL, 2.6 mmol) in 1,4-dioxane (50 µL) was degassed <i>via</i> nitrogen bubble for 15 mins. Then the mixture was added Pd(PPh<sub>3</sub>)<sub>4</sub> (150 mg, 0.13 mmol) and aqueous Na<sub>2</sub>CO<sub>3</sub> (24 µL, 5.7 mmol) and heated to 90 °C for 30 mins. The reaction was cooled to room temperature and poured into ethyl acetate (50 mL). The mixture was extracted with ethyl acetate, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified via a flash column using 10% ethyl acetate in hexanes as an eluent. The product containing fractions were concentrated to give 5-bromo-2-fluoro-3-phenylpyridine (2.2) (326 mg, 49.8% yield).</p><heading id="h0014">Step 2. Preparation of 1-(5-bromo-3-phenylpyridin-2-yl)hydrazine</heading><p id="p0059" num="0059"><chemistry id="chem0015" num="0015"><img id="ib0015" file="imgb0015.tif" wi="32" he="28" img-content="chem" img-format="tif"/></chemistry></p><p id="p0060" num="0060">Hydrazine monohydrate (1.76 mL, 13 mmol) was added into a solution of 5-bromo-2-fluoro-3-phenylpyridine (326 mg, 1.29 mmol) in isopropanol (12 mL) at room temperature. The reaction mixture was heated gradually to 82 °C over 5h and<!-- EPO <DP n="26"> --> continued to heat overnight, cooled to room temperature and concentrated to give 1-(5-bromo-3-phenylpyridin-2-yl)hydrazine which was used directly in next step.</p><heading id="h0015">Step 3. Preparation of 6-bromo-8-phenyl-[1,2,4]triazolo[4,3-a]pyridine</heading><p id="p0061" num="0061"><chemistry id="chem0016" num="0016"><img id="ib0016" file="imgb0016.tif" wi="27" he="28" img-content="chem" img-format="tif"/></chemistry></p><p id="p0062" num="0062">Trimethyl orthoformate (564 µL, 5.16 mmol) was added into a solution of 1-(5-bromo-3-phenylpyridin-2-yl)hydrazine (1.29 mmol, crude) in CH<sub>2</sub>Cl<sub>2</sub> (12 mL). TFA (100 µL, 1.29 mmol) was added after 15 mins. The reaction mixture was stirred at room temperature for 30 mins and then concentrated. The residue was purified by a flash column using a gradient of ethyl acetate (50 - 80%) in heptane as an eluent. The product containing fractions were concentrated to give 6-bromo-8-phenyl-[1,2,4]triazolo[4,3-a]pyridine (328.7 mg, 85% yield).</p><heading id="h0016">Step 4. Preparation of (Z)-6-(2-ethoxyvinyl)-8-phenyl-[1,2,4]triazolo[4,3-a]pyridine</heading><p id="p0063" num="0063"><chemistry id="chem0017" num="0017"><img id="ib0017" file="imgb0017.tif" wi="30" he="27" img-content="chem" img-format="tif"/></chemistry></p><p id="p0064" num="0064">A mixture of 6-bromo-8-phenyl-[1,2,4]triazolo[4,3-a]pyridine (26.1 mg, 0.095 mmol), (Z)-tributyl(2-ethoxyvinyl)stannane (34.6 mg, 0.095 mmol) and tetraethylammonium chloride (16 mg, 0.095 mmol) in DMF (0.5 mL) was added PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (2 mg, 0.005 mmol). The reaction was heated at 80 °C overnight, cooled to rt, added an aqueous of KF (1.1 eq) in water (95 µL) and further stirred for 30 mins, then diluted with ethyl acetate (2 mL), filtered and rinsed with ethyl acetate (8 mL). The mixture was then washed with water (2 x 2 mL), separated, dried and concentrated. The residue was purified by a flash column using a gradient of ethyl acetate in hexane (50-75 %) as an eluent to give compound (13 mg, 52% yield).<!-- EPO <DP n="27"> --></p><heading id="h0017">Step 5. Preparation of 5-(8-phenyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-N-propylthiazol-2-amine</heading><p id="p0065" num="0065">A solution of (Z)-6-(2-ethoxyvinyl)-8-phenyl-[1,2,4]triazolo[4,3-a]pyridine (13 mg, 0.049 mmol) in 1,4-dioxane (1 mL) and water (1 mL) was added NBS (9.4 mg, 0.054 mmol) and stirred at rt for 1h. The mixture was then added 1-propylthiaurea (6.4 mg, 0.054 mmol), heated to 85 - 90 °C for 10h, then cooled and concentrated. The residue was dissolved in a mixture of 20 % MeOH in dichloromethane and purified by 500 µm silica gel prep plate using 75% ethyl acetate in hexanes as an eluent. The product was collected (4.5 mg, 27.4% yield). LCMS :336.55 (M+H), Tr 2.98 min, (Conditions A).</p><heading id="h0018">EXAMPLE 6</heading><heading id="h0019">5-(8-(2-Fluorophenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-N-isopropylthiazol-2-amine</heading><p id="p0066" num="0066"><chemistry id="chem0018" num="0018"><img id="ib0018" file="imgb0018.tif" wi="40" he="42" img-content="chem" img-format="tif"/></chemistry></p><heading id="h0020">Step 1. Preparation of 5-bromo-6-methoxynicotinaldehyde</heading><p id="p0067" num="0067"><chemistry id="chem0019" num="0019"><img id="ib0019" file="imgb0019.tif" wi="29" he="24" img-content="chem" img-format="tif"/></chemistry></p><p id="p0068" num="0068">To a mixture of 6-methoxynicotinaldehyde (3 g, 0.0219 mol) and NaOAc (3.5 g, 0.0427 mol) in HOAc (10 mL) was added a solution of bromine (1.64 mL, 0.031 mol) in HOAc (10 mL) over 30 mins via an additional funnel. The mixture was heated to 90 °C for 5h, cooled to rt. The reaction was added iced water (100 mL), neutralized to pH = 7.5 with aq. NaOH (5 N), extracted with ethyl acetate (4 X 50 mL), washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified via flash column using dichloromethane as an eluent. The product<!-- EPO <DP n="28"> --> containing fractions were collected and concentrated to give 5-bromo-6-methoxynicotinaldehyde (1.854g, 39% yield).</p><heading id="h0021">Step 2. Preparation of (<i>E</i>)-3-bromo-2-methoxy-5-(2-methoxyvinyl)pyridine</heading><p id="p0069" num="0069"><chemistry id="chem0020" num="0020"><img id="ib0020" file="imgb0020.tif" wi="37" he="19" img-content="chem" img-format="tif"/></chemistry></p><p id="p0070" num="0070">A solution of (methoxymethyl)triphenylphosphonium chloride (737 mg, 2.15 mmol) in THF (10 mL) at -78 °C was added t-BuOK (1 M in THF, 2.15 mL, 2.15 mmol) and stirred at 0 °C for 30 mins, then added dropwisely a solution of 5-bromo-6-methoxynicotinaldehyde (310 mg, 1.435 mmol) in THF (6 mL) at 0 °C via cannulation. The mixture was stirred and gradually warmed to rt overnight. The mixture was concentrated and the residue was purified via a flash column using 50% ethyl acetate in hexanes as an eluent. The product containing fractions were concentrated to give (<i>E</i>)-3-bromo-2-methoxy-5-(2-methoxyvinyl)pyridine (296.9 mg, 85% yield).</p><heading id="h0022">Step 3. Preparation of 5-(5-bromo-6-methoxypyridin-3-yl)-N-isopropylthiazol-2-amine</heading><p id="p0071" num="0071"><chemistry id="chem0021" num="0021"><img id="ib0021" file="imgb0021.tif" wi="40" he="34" img-content="chem" img-format="tif"/></chemistry></p><p id="p0072" num="0072">A solution of 5-(5-bromo-6-methoxypyridin-3-yl)-N-isopropylthiazole-2-amine (1.25 g, 7.56 mmol) in a mixture of 1:1 ratio 1,4-dioxane (38 mL) and water (38 mL) was added NBS (1.57 g, 8.32 mmol) and stirred for 1.5h. The mixture was then added isopropylthiourea (0.983 g, 8.32 mmol) and heated to 75 °C for 5h. The mixture was cooled and concentrated. The residue was neutralized with concentrated NH<sub>4</sub>OH and the precipitate was sonicated, filtered, rinsed with water and dried to give the product.<!-- EPO <DP n="29"> --></p><heading id="h0023">Step 4. Preparation of 3-bromo-5-(2-(isopropylamino)thiazol-5-yl)pyridin-2(1H)-one</heading><p id="p0073" num="0073"><chemistry id="chem0022" num="0022"><img id="ib0022" file="imgb0022.tif" wi="37" he="34" img-content="chem" img-format="tif"/></chemistry></p><p id="p0074" num="0074">A solution of 5-(5-bromo-6-methoxypyridin-3-yl)-N-isopropylthiazol-2-amine (390 mg, 1.18 mmol) in THF (1 mL) was added HCl (4 N, 10 mL) and heated at 90 °C overnight. The mixture was cooled to rt, neutralized with aq NaOH (5 N) and stirred for 1h. The solid was filtered, rinsed with water and dried to give 3-bromo-5-(2-(isopropylamino)thiazol-5-yl)pyridin-2(1H)-one (359.4 mg, 96%).</p><heading id="h0024">Step 5. Preparation of 5-(5-bromo-6-chloropyridin-3-yl)-N-isopropylthiazol-2-amine</heading><p id="p0075" num="0075"><chemistry id="chem0023" num="0023"><img id="ib0023" file="imgb0023.tif" wi="37" he="34" img-content="chem" img-format="tif"/></chemistry></p><p id="p0076" num="0076">A mixture of 3-bromo-5-(2-(isopropylamino)thiazol-5-yl)pyridin-2(1H)-one (359 mg, 1.14 mmol) was heated at 100 °C overnight and cooled to rt. The mixture was concentrated and added dichloromethane (20 mL), water (3 mL) and saturated aq NaHCO<sub>3</sub> (3mL). The mixture was stirred rapidly and separated. The aqueous was extracted with dichloromethane twice. The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give the product (378 mg, 99% yield).</p><heading id="h0025">Step 6. Preparation of 5-(8-bromo-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-N-isopropylthiazol-2-amine</heading><p id="p0077" num="0077"><chemistry id="chem0024" num="0024"><img id="ib0024" file="imgb0024.tif" wi="40" he="34" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="30"> --></p><p id="p0078" num="0078">To a mixture of 5-(5-bromo-6-chloropyridin-3-yl)-N-isopropylthiazol-2-amine (341 mg, 1.02 mmol) in n-BuOH (5 mL) was added hydrazine monohydrate (806 µL, 2.55 mmol). The reaction mixture was heated at 105 °C in a sealed tube overnight, cooled and concentrated. The residue was added trimethyl orthoformate (335 µL, 3.06 mmol), CH<sub>2</sub>Cl<sub>2</sub> (5 mL) and stirred for 10 mins, then added TFA (118 µL, 1.53 mmol). The reaction was continued to stir for 45 mins, and then concentrated. The residue was added water (10 mL), neutralized with NaHCO<sub>3</sub>, stirred overnight, filtered and rinsed with water. The dried solid was purified by a flash column using 5% MeOH in dichloromethane as an eluent. The product containing fractions were concentrated to give the product (208.1 mg, 60% yield in two-step).</p><heading id="h0026">Step 7. Preparation of 5-(8-(2-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-N-isopropylthiazol-2-amine</heading><p id="p0079" num="0079">A mixture of 5-(8-bromo-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-N-isopropylthiazol-2-amine (19.6 mg, 0.0579 mmol) and 2-fluorophenylboronic acid (12.7 mg, 0.081 mmol) in toluene (0.58 mL) was degassed via nitrogen bubble, then was added Pd(PPh<sub>3</sub>)<sub>4</sub> (3.3 mg, 0.003 mmol), aqueous K<sub>3</sub>PO<sub>4</sub> (2 M, 58 µL, 0.116 mmol) and ethanol (84 µL). The reaction mixture was heated to 100 °C overnight, cooled to rt, diluted with EtOH (1 mL), filtered and concentrated. The residues were purified directly by reverse phase preparative HPLC and the product containing fractions were concentrated and neutralized with aqueous NaHCO<sub>3</sub> to precipitate the product. The solids were filtered, washed and dried to give (9.7 mg, 47% yield). LCMS 354.23, Tr 3.50 min (Conditions A).</p><heading id="h0027">EXAMPLES 7 TO 29</heading><p id="p0080" num="0080">Additional compounds of the general formula 3.I prepared according to the methods previously described in Schemes 2 and 3 are illustrated in Table 1.<!-- EPO <DP n="31"> -->
<tables id="tabl0001" num="0001"><table frame="all"><title>TABLE 1</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="24mm"/><colspec colnum="2" colname="col2" colwidth="40mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="25mm"/><thead><row><entry align="center" valign="top">Example No.</entry><entry align="center" valign="top">Structure</entry><entry align="center" valign="top">LCMS</entry><entry align="center" valign="top">HPLC Tr (min)</entry></row></thead><tbody><row><entry align="center">7</entry><entry align="center"><chemistry id="chem0025" num="0025"><img id="ib0025" file="imgb0025.tif" wi="27" he="38" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">322.47</entry><entry align="center">2.69, A</entry></row><row><entry align="center">8</entry><entry align="center"><chemistry id="chem0026" num="0026"><img id="ib0026" file="imgb0026.tif" wi="27" he="37" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">336.54</entry><entry align="center">2.87, A</entry></row><row><entry align="center">9</entry><entry align="center"><chemistry id="chem0027" num="0027"><img id="ib0027" file="imgb0027.tif" wi="25" he="37" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">350.5</entry><entry align="center">3.10, A</entry></row><row><entry align="center">10</entry><entry align="center"><chemistry id="chem0028" num="0028"><img id="ib0028" file="imgb0028.tif" wi="27" he="37" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">370.22</entry><entry align="center">2.94, A</entry></row><!-- EPO <DP n="32"> --><row><entry align="center">13</entry><entry align="center"><chemistry id="chem0029" num="0029"><img id="ib0029" file="imgb0029.tif" wi="36" he="39" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">370.2</entry><entry align="center">3.33, A</entry></row><row><entry align="center">14</entry><entry align="center"><chemistry id="chem0030" num="0030"><img id="ib0030" file="imgb0030.tif" wi="32" he="39" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">370.21</entry><entry align="center">3.33, A</entry></row><row><entry align="center">15</entry><entry align="center"><chemistry id="chem0031" num="0031"><img id="ib0031" file="imgb0031.tif" wi="36" he="39" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">354.18</entry><entry align="center">3.01, A</entry></row><row><entry align="center">16</entry><entry align="center"><chemistry id="chem0032" num="0032"><img id="ib0032" file="imgb0032.tif" wi="32" he="39" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">354.19</entry><entry align="center">3.02, A</entry></row><row><entry align="center">19</entry><entry align="center"><chemistry id="chem0033" num="0033"><img id="ib0033" file="imgb0033.tif" wi="36" he="38" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">361.27</entry><entry align="center">2.67, B</entry></row><!-- EPO <DP n="33"> --><row><entry align="center">21</entry><entry align="center"><chemistry id="chem0034" num="0034"><img id="ib0034" file="imgb0034.tif" wi="32" he="38" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">372.2</entry><entry align="center">3.39, B</entry></row><row><entry align="center">22</entry><entry align="center"><chemistry id="chem0035" num="0035"><img id="ib0035" file="imgb0035.tif" wi="35" he="38" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">372.22</entry><entry align="center">3.06, B</entry></row><row><entry align="center">23</entry><entry align="center"><chemistry id="chem0036" num="0036"><img id="ib0036" file="imgb0036.tif" wi="35" he="38" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">372.23</entry><entry align="center">3.16, B</entry></row><row><entry align="center">25</entry><entry align="center"><chemistry id="chem0037" num="0037"><img id="ib0037" file="imgb0037.tif" wi="32" he="38" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">372.22</entry><entry align="center">3.11, A</entry></row><!-- EPO <DP n="34"> --><row><entry align="center">26</entry><entry align="center"><chemistry id="chem0038" num="0038"><img id="ib0038" file="imgb0038.tif" wi="32" he="39" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">388.18</entry><entry align="center">3.64, B</entry></row><row><entry align="center">27</entry><entry align="center"><chemistry id="chem0039" num="0039"><img id="ib0039" file="imgb0039.tif" wi="35" he="38" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">268.25</entry><entry align="center">3.19, B</entry></row><row><entry align="center">28</entry><entry align="center"><chemistry id="chem0040" num="0040"><img id="ib0040" file="imgb0040.tif" wi="35" he="37" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">352.2</entry><entry align="center">2.69, B</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="35"> --></p><heading id="h0028">REFERENCE EXAMPLE 70</heading><heading id="h0029">Preparation of 5-(8-(2,4-difluorophenyl)H-imidazo[1,2-a]pyridin-6-yl)-N-(3-methylbutan-2-yl)thiazol-2-amine</heading><p id="p0081" num="0081"><chemistry id="chem0041" num="0041"><img id="ib0041" file="imgb0041.tif" wi="42" he="52" img-content="chem" img-format="tif"/></chemistry></p><p id="p0082" num="0082">A solution of 8-(2,4-difluorophenyl)H-imidazo[1,2-a]pyridin-6-ylboronic acid (5) (20 mg, 0.073 mmol) and <i>tert</i>-butyl 5-bromothiazol-2-yl(3-methylbutan-2-yl)carbamate (25 mg, 0.073 mmol) in toluene (2 mL) and ethanol (100 µL) was degassed via nitrogen bubble for 20 mins. The mixture was then added Pb(PPh<sub>3</sub>)<sub>4</sub> (4.2 mg, 0.00365 mmol) and K<sub>3</sub>PO<sub>4</sub> (2 M, 73 µL, 0.146 mmol) and heated to 80 °C overnight. The reaction was cooled and extracted with ethyl acetate (2 X 10 mL), washed with brine, dried over and concentrated. The residue was purified via a flash column using a gradient of ethyl acetate in hexanes (10-40 %). The product containing fractions were concentrated and was added dichloromethane (2 mL) and TFA (500 µL). The mixture was stirred at rt for 4h and concentrated. The residue was purified directly by reverse phase preparative HPLC and the product containing fractions were concentrated and neutralized with aqueous NaHCO<sub>3</sub> to precipitate the products. The solids were filtered, washed and dried to give 5-(8-(2,4-difluorophenyl)H-imidazo[1,2-a]pyridin-6-yl)-N-(3-methylbutan-2-yl)thiazol-2-amine (6) (10 mg, 34.4% yield).</p><heading id="h0030">REFERENCE EXAMPLES 71 TO 160</heading><p id="p0083" num="0083">Additional compounds prepared according to the general methods outlined above are included in Table 3.<!-- EPO <DP n="36"> -->
<tables id="tabl0002" num="0002"><table frame="all"><title>TABLE 3</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="24mm"/><colspec colnum="2" colname="col2" colwidth="52mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="25mm"/><thead><row><entry align="center" valign="top">Example No.</entry><entry align="center" valign="top">Structure</entry><entry align="center" valign="top">LCMS</entry><entry align="center" valign="top">HPLC Tr (min)</entry></row></thead><tbody><row><entry align="center">71</entry><entry align="center"><chemistry id="chem0042" num="0042"><img id="ib0042" file="imgb0042.tif" wi="38" he="39" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">349.22</entry><entry align="center">2.67, B</entry></row><row><entry align="center">72</entry><entry align="center"><chemistry id="chem0043" num="0043"><img id="ib0043" file="imgb0043.tif" wi="38" he="38" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">385.17</entry><entry align="center">2.92, B</entry></row><row><entry align="center">73</entry><entry align="center"><chemistry id="chem0044" num="0044"><img id="ib0044" file="imgb0044.tif" wi="38" he="38" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">367.23</entry><entry align="center">2.73, B</entry></row><row><entry align="center">74</entry><entry align="center"><chemistry id="chem0045" num="0045"><img id="ib0045" file="imgb0045.tif" wi="35" he="39" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">385.22</entry><entry align="center">2.73, B</entry></row><!-- EPO <DP n="37"> --><row><entry align="center">76</entry><entry align="center"><chemistry id="chem0046" num="0046"><img id="ib0046" file="imgb0046.tif" wi="34" he="39" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">383.22</entry><entry align="center">3.02, B</entry></row><!-- EPO <DP n="38"> --><row><entry align="center">83</entry><entry align="center"><chemistry id="chem0047" num="0047"><img id="ib0047" file="imgb0047.tif" wi="39" he="18" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">397.2</entry><entry align="center">2.90, B</entry></row><row><entry align="center">86</entry><entry align="center"><chemistry id="chem0048" num="0048"><img id="ib0048" file="imgb0048.tif" wi="39" he="18" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">363.3</entry><entry align="center">2.64, B</entry></row><row><entry align="center">87</entry><entry align="center"><chemistry id="chem0049" num="0049"><img id="ib0049" file="imgb0049.tif" wi="39" he="20" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">381.3</entry><entry align="center">2.71, B</entry></row><!-- EPO <DP n="39"> --><row><entry align="center">91</entry><entry align="center"><chemistry id="chem0050" num="0050"><img id="ib0050" file="imgb0050.tif" wi="38" he="38" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">365.25</entry><entry align="center">2.51, B</entry></row><row><entry align="center">92</entry><entry align="center"><chemistry id="chem0051" num="0051"><img id="ib0051" file="imgb0051.tif" wi="38" he="38" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">379.21</entry><entry align="center">2.77, B</entry></row><row><entry align="center">94</entry><entry align="center"><chemistry id="chem0052" num="0052"><img id="ib0052" file="imgb0052.tif" wi="35" he="38" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">374.16</entry><entry align="center">2.53, B</entry></row><!-- EPO <DP n="40"> --><row><entry align="center">103</entry><entry align="center"><chemistry id="chem0053" num="0053"><img id="ib0053" file="imgb0053.tif" wi="39" he="20" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">399.2</entry><entry align="center">2.82, B</entry></row><!-- EPO <DP n="41"> --><row><entry align="center">113</entry><entry align="center"><chemistry id="chem0054" num="0054"><img id="ib0054" file="imgb0054.tif" wi="39" he="30" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">381.3</entry><entry align="center">2.22, C</entry></row><row><entry align="center">114</entry><entry align="center"><chemistry id="chem0055" num="0055"><img id="ib0055" file="imgb0055.tif" wi="39" he="30" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">381.3</entry><entry align="center">2.23, C</entry></row><row><entry align="center">115</entry><entry align="center"><chemistry id="chem0056" num="0056"><img id="ib0056" file="imgb0056.tif" wi="39" he="29" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">353.3</entry><entry align="center">1.85, C</entry></row><row><entry align="center">116</entry><entry align="center"><chemistry id="chem0057" num="0057"><img id="ib0057" file="imgb0057.tif" wi="39" he="30" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">353.4</entry><entry align="center">1.84, C</entry></row><row><entry align="center">117</entry><entry align="center"><chemistry id="chem0058" num="0058"><img id="ib0058" file="imgb0058.tif" wi="41" he="33" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">388.4</entry><entry align="center">2.07, C</entry></row><!-- EPO <DP n="42"> --><row><entry align="center">118</entry><entry align="center"><chemistry id="chem0059" num="0059"><img id="ib0059" file="imgb0059.tif" wi="39" he="30" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">377.4</entry><entry align="center">2.47, C</entry></row><row><entry align="center">119</entry><entry align="center"><chemistry id="chem0060" num="0060"><img id="ib0060" file="imgb0060.tif" wi="39" he="30" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">349.4</entry><entry align="center">1.93, C</entry></row><row><entry align="center">120</entry><entry align="center"><chemistry id="chem0061" num="0061"><img id="ib0061" file="imgb0061.tif" wi="39" he="30" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">377.4</entry><entry align="center">2.32, C</entry></row><row><entry align="center">121</entry><entry align="center"><chemistry id="chem0062" num="0062"><img id="ib0062" file="imgb0062.tif" wi="39" he="30" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">363.4</entry><entry align="center">2.05, C</entry></row><row><entry align="center">122</entry><entry align="center"><chemistry id="chem0063" num="0063"><img id="ib0063" file="imgb0063.tif" wi="39" he="29" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">363.4</entry><entry align="center">2.19, C</entry></row><row><entry align="center">123</entry><entry align="center"><chemistry id="chem0064" num="0064"><img id="ib0064" file="imgb0064.tif" wi="39" he="30" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">349.3</entry><entry align="center">2.11, C</entry></row><row><entry align="center">124</entry><entry align="center"><chemistry id="chem0065" num="0065"><img id="ib0065" file="imgb0065.tif" wi="40" he="36" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">405.3</entry><entry align="center">2.15, C</entry></row><!-- EPO <DP n="43"> --><row><entry align="center">125</entry><entry align="center"><chemistry id="chem0066" num="0066"><img id="ib0066" file="imgb0066.tif" wi="39" he="30" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">391.4</entry><entry align="center">2.56, C</entry></row><row><entry align="center">126</entry><entry align="center"><chemistry id="chem0067" num="0067"><img id="ib0067" file="imgb0067.tif" wi="40" he="31" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">413.4</entry><entry align="center">2.58, C</entry></row><row><entry align="center">127</entry><entry align="center"><chemistry id="chem0068" num="0068"><img id="ib0068" file="imgb0068.tif" wi="41" he="30" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">388.4</entry><entry align="center">2.05, C</entry></row><row><entry align="center">128</entry><entry align="center"><chemistry id="chem0069" num="0069"><img id="ib0069" file="imgb0069.tif" wi="41" he="33" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">360.3</entry><entry align="center">1.7, C</entry></row><row><entry align="center">129</entry><entry align="center"><chemistry id="chem0070" num="0070"><img id="ib0070" file="imgb0070.tif" wi="41" he="30" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">360.3</entry><entry align="center">1.68, C</entry></row><row><entry align="center">130</entry><entry align="center"><chemistry id="chem0071" num="0071"><img id="ib0071" file="imgb0071.tif" wi="43" he="30" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">363.3</entry><entry align="center">2.67, C</entry></row><row><entry align="center">131</entry><entry align="center"><chemistry id="chem0072" num="0072"><img id="ib0072" file="imgb0072.tif" wi="39" he="30" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">363.3</entry><entry align="center">2.71, C</entry></row><!-- EPO <DP n="44"> --><row><entry align="center">132</entry><entry align="center"><chemistry id="chem0073" num="0073"><img id="ib0073" file="imgb0073.tif" wi="43" he="29" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">363.4</entry><entry align="center">2.13, C</entry></row><row><entry align="center">133</entry><entry align="center"><chemistry id="chem0074" num="0074"><img id="ib0074" file="imgb0074.tif" wi="43" he="29" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">365.4</entry><entry align="center">1.55, C</entry></row><row><entry align="center">134</entry><entry align="center"><chemistry id="chem0075" num="0075"><img id="ib0075" file="imgb0075.tif" wi="29" he="34" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">349.4</entry><entry align="center">2.44, C</entry></row><row><entry align="center">135</entry><entry align="center"><chemistry id="chem0076" num="0076"><img id="ib0076" file="imgb0076.tif" wi="47" he="29" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">407.4</entry><entry align="center">1.81, C</entry></row><row><entry align="center">136</entry><entry align="center"><chemistry id="chem0077" num="0077"><img id="ib0077" file="imgb0077.tif" wi="43" he="30" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">367.4</entry><entry align="center">2.07, C</entry></row><row><entry align="center">137</entry><entry align="center"><chemistry id="chem0078" num="0078"><img id="ib0078" file="imgb0078.tif" wi="39" he="29" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">335.4</entry><entry align="center">2.29, C</entry></row><!-- EPO <DP n="45"> --><row><entry align="center">139</entry><entry align="center"><chemistry id="chem0079" num="0079"><img id="ib0079" file="imgb0079.tif" wi="39" he="28" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">341.1</entry><entry align="center">2.12, C</entry></row><row><entry align="center">140</entry><entry align="center"><chemistry id="chem0080" num="0080"><img id="ib0080" file="imgb0080.tif" wi="47" he="29" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">365.0</entry><entry align="center">1.77, C</entry></row><row><entry align="center">145</entry><entry align="center"><chemistry id="chem0081" num="0081"><img id="ib0081" file="imgb0081.tif" wi="35" he="29" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">321.0</entry><entry align="center">1.55, C</entry></row><!-- EPO <DP n="46"> --><row><entry align="center">146</entry><entry align="center"><chemistry id="chem0082" num="0082"><img id="ib0082" file="imgb0082.tif" wi="43" he="29" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">349.0</entry><entry align="center">2.00, C</entry></row><row><entry align="center">149</entry><entry align="center"><chemistry id="chem0083" num="0083"><img id="ib0083" file="imgb0083.tif" wi="39" he="26" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">348.0</entry><entry align="center">2.86, C</entry></row><row><entry align="center">150</entry><entry align="center"><chemistry id="chem0084" num="0084"><img id="ib0084" file="imgb0084.tif" wi="39" he="27" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">324.1</entry><entry align="center">1.75, C</entry></row><row><entry align="center">151</entry><entry align="center"><chemistry id="chem0085" num="0085"><img id="ib0085" file="imgb0085.tif" wi="39" he="28" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">355.0</entry><entry align="center">1.83, C</entry></row><!-- EPO <DP n="47"> --><row><entry align="center">157</entry><entry align="center"><chemistry id="chem0086" num="0086"><img id="ib0086" file="imgb0086.tif" wi="47" he="29" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">407.3</entry><entry align="center">1.96, C</entry></row><row><entry align="center">158</entry><entry align="center"><chemistry id="chem0087" num="0087"><img id="ib0087" file="imgb0087.tif" wi="43" he="29" img-content="chem" img-format="tif"/></chemistry></entry><entry align="char" char="." charoff="38">379.3</entry><entry align="center">1.62, C</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="48"> --></p><heading id="h0031">REFERENCE EXAMPLE 171</heading><heading id="h0032">N-Isopropyl-5-(8-phenylimidazo[1,2-a]pyrazin-6-yl)thiazol-2-amine</heading><p id="p0084" num="0084"><chemistry id="chem0088" num="0088"><img id="ib0088" file="imgb0088.tif" wi="36" he="49" img-content="chem" img-format="tif"/></chemistry></p><heading id="h0033">Step 1. Preparation of 5-bromo-3-phenylpyrazin-2-amine</heading><p id="p0085" num="0085"><chemistry id="chem0089" num="0089"><img id="ib0089" file="imgb0089.tif" wi="28" he="28" img-content="chem" img-format="tif"/></chemistry></p><p id="p0086" num="0086">A mixture of 3,5-dibromopyrazin-2-amine (214 mg, 0.83 mmol) and phenyl boronic acid (100 mg, 0.8 mmol) in toluene (8 mL) was degassed and backfilled with nitrogen 3 times. Pd(PPh<sub>3</sub>)<sub>4</sub> (46 mg) was added followed by 2M K<sub>3</sub>PO<sub>4</sub> (0.8 mL) and EtOH (1 mL). The mixture was heated at reflux for 18 h. The solution was cooled to room temperature, partitioned between EtOAc (25 mL) and water (5 mL). The layers were separated and the organic layer dried over Na<sub>2</sub>SO<sub>4</sub>,<!-- EPO <DP n="49"> --> filtered and concentrated to an oil which was purified via silica gel chromatography (15% EtOAc/heptane) to afford the product (187 mg, 95% yield).</p><heading id="h0034">Step 2. Preparation of <i>tert</i>-butyl 2-(5-amino-6-phenylpyrazin-2-yl)thiazol-5-yl(isopropyl)carbamate</heading><p id="p0087" num="0087"><chemistry id="chem0090" num="0090"><img id="ib0090" file="imgb0090.tif" wi="51" he="50" img-content="chem" img-format="tif"/></chemistry></p><p id="p0088" num="0088">To a solution of 5-bromo-3-phenylpyrazin-2-amine (26 mg, 0.1 mmol) and tert-butyl isopropyl(5-(tributylstannyl)thiazol-2-yl)carbamate (80 mg, 0.15 mmol) in DMF (0.4 mL) was added PdCl<sub>2</sub>(PPh<sub>3</sub>)2 (7 mg, 0.01 mmol) followed by DIPEA (0.044 mL, 0.25 mmol) and the reaction heated at 85 °C for 18h. The reaction mixture was cooled to room temperature and diluted with EtOAc (6 mL) and water (2 mL), the layers were separated and the aqueous layer further extracted with EtOAc. The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated <i>in vacuo.</i> The product was isolated via column chromatography (SiO<sub>2</sub>, 25% EtOAc/heptane) to afford the product (44 mg, 100% yield).</p><heading id="h0035">Step 3. Preparation of <i>tert</i>-butyl isopropyl(2-(8-phenylimidazo[1,2-a]pyrazin-6-yl)thiazol-5-yl)carbamate</heading><p id="p0089" num="0089"><chemistry id="chem0091" num="0091"><img id="ib0091" file="imgb0091.tif" wi="50" he="50" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="50"> --></p><p id="p0090" num="0090">A solution of <i>tert</i>-butyl 2-(5-amino-6-phenylpyrazin-2-yl)thiazol-5-yl(isopropyl)carbamate (23.7 mg, 0.06 mmol) in EtOH (0.25 mL) was added chloroacetaldehyde (11.8 µL, 50% in water) and the reaction mixture was then heated to 60 °C for 24h and then concentrated to dryness. The crude product was dried under high vacuum and used without further purification.</p><heading id="h0036">Step 4. Preparation of N-isopropyl-5-(8-phenylimidazo[1,2-a]pyrazin-6-yl)thiazol-2-amine</heading><p id="p0091" num="0091">The crude <i>tert</i>-butyl isopropyl(2-(8-phenylimidazo[1,2-a]pyrazin-6-yl)thiazol-5-yl)carbamate prepared in step 3, was dissolved in dichloromethane (0.5 mL) and added TFA (0.5 mL). The reaction mixture was stirred for 4 h and the solvents were then removed. The residue was dissolved in water (0.5 mL) and neutralized with NaHCO3 (sat. aq.). The solids were stirred overnight, filtered, and purified via prep plate chromatography (50% EtOAc/heptane) to afford N-isopropyl-5-(8-phenylimidazo[1,2-a]pyrazin-6-yl)thiazol-2-amine as a yellow solid (9.5 mg, 49% yield). LCMS 336.2 (M+H), HPLC 3.49 min (Conditions B).</p><heading id="h0037">REFERENCE EXAMPLES 172 TO 175</heading><p id="p0092" num="0092">Additional compounds prepared according to the general methods outlined above are included in Table 5.
<tables id="tabl0003" num="0003"><table frame="all"><title>TABLE 5</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="24mm"/><colspec colnum="2" colname="col2" colwidth="42mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="14mm"/><thead><row><entry align="center" valign="top">Example No.</entry><entry align="center" valign="top">Structure</entry><entry align="center" valign="top">LCMS</entry><entry align="center" valign="top">HPLC</entry></row></thead><tbody><row><entry align="center">172</entry><entry align="center"><chemistry id="chem0092" num="0092"><img id="ib0092" file="imgb0092.tif" wi="38" he="39" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">368.2</entry><entry align="center">3.20, B</entry></row><!-- EPO <DP n="51"> --><row><entry align="center">175</entry><entry align="center"><chemistry id="chem0093" num="0093"><img id="ib0093" file="imgb0093.tif" wi="37" he="39" img-content="chem" img-format="tif"/></chemistry></entry><entry align="center">366.4</entry><entry align="center">3.74, B</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="52"> --></p><heading id="h0038">EXAMPLE 192</heading><p id="p0093" num="0093">Scheme 1, 2 or 3 above is used to prepare triazolopyridine compounds similar to the imidazopyridine compounds of Examples 71-74, 76, 83, 86, 87, 91, 92, 94, 103, 113-137, 139, 140, 145-151, 157 and 158 except that the imidazo ring in the examples is a triazolo ring.</p><heading id="h0039">EXAMPLE 193</heading><p id="p0094" num="0094">Scheme 1, 2 or 3 above is used to prepare triazolopyridine compounds similar to the imidazopyrazine compounds of Examples 171, 172 and 175 except that the<!-- EPO <DP n="53"> --> imidazo ring in the examples is a triazolo ring and the pyrazine ring in the examples is a pyridine ring.</p><heading id="h0040">TEST DATA</heading><p id="p0095" num="0095">The data in Table 8, below, describes the activity of selected examples. The data was obtained using the assays described above.</p><p id="p0096" num="0096">Preferred triazolopyridine compounds of the invention have a p38 inhibition activity (IC<sub>50</sub>) of less than about 0.1 µM, preferably less than about 0.05 µM, more preferably less than about 0.02 µM and most preferably less than about 0.01 µM. Preferred suitable ranges for p38 inhibition activity (IC<sub>50</sub>) include about 0.01 µM to about 0.1 µM, preferably about 0.01 µM to about 0.02 µM.
<tables id="tabl0004" num="0004"><table frame="all"><title>TABLE 8</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="24mm"/><colspec colnum="2" colname="col2" colwidth="25mm"/><thead><row><entry align="center" valign="top">Example No.</entry><entry align="center" valign="top">p38 IC50 (uM)</entry></row></thead><tbody><row><entry align="center">6</entry><entry align="char" char="." charoff="8">0.013</entry></row><row><entry align="center">10</entry><entry align="char" char="." charoff="8">0.015</entry></row><row><entry align="center">15</entry><entry align="char" char="." charoff="8">0.091</entry></row><row><entry align="center">26</entry><entry align="char" char="." charoff="8">0.604</entry></row></tbody></tgroup></table></tables></p></description><claims mxw-id="PCLM56979473" lang="DE" load-source="patent-office"><!-- EPO <DP n="58"> --><claim id="c-de-01-0001" num="0001"><claim-text>Verbindung der Formel I:
<chemistry id="chem0105" num="0105"><img id="ib0105" file="imgb0105.tif" wi="38" he="34" img-content="chem" img-format="tif"/></chemistry>
und Enantiomere, Diastereomere und pharmazeutisch verträgliche Salze davon, wobei:
<claim-text>R<sup>1</sup> Thiazol-5-yl ist, das an Position 2 mit C<sub>1-6</sub>-Alkylamino substituiert ist; und</claim-text>
<claim-text>R<sup>2</sup> Phenyl ist, das wahlweise mit einem oder mehreren Substituenten ausgewählt aus Halo, Cyano, C<sub>1</sub>-C<sub>4</sub>-Alkyl und Hydroxy substituiert ist.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verbindung nach Anspruch 1, wobei R<sup>1</sup> ausgewählt ist aus:
<chemistry id="chem0106" num="0106"><img id="ib0106" file="imgb0106.tif" wi="105" he="34" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verbindung nach einem der Ansprüche 1 oder 2, wobei die Verbindung ausgewählt ist aus
<chemistry id="chem0107" num="0107"><img id="ib0107" file="imgb0107.tif" wi="134" he="50" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0108" num="0108"><img id="ib0108" file="imgb0108.tif" wi="94" he="48" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="59"> -->
<chemistry id="chem0109" num="0109"><img id="ib0109" file="imgb0109.tif" wi="91" he="48" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0110" num="0110"><img id="ib0110" file="imgb0110.tif" wi="94" he="48" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0111" num="0111"><img id="ib0111" file="imgb0111.tif" wi="87" he="45" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0112" num="0112"><img id="ib0112" file="imgb0112.tif" wi="88" he="45" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0113" num="0113"><img id="ib0113" file="imgb0113.tif" wi="89" he="45" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="60"> -->
<chemistry id="chem0114" num="0114"><img id="ib0114" file="imgb0114.tif" wi="96" he="49" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0115" num="0115"><img id="ib0115" file="imgb0115.tif" wi="42" he="41" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Pharmazeutische Zusammensetzung umfassend mindestens eine Verbindung nach einem der Ansprüche 1-3 und einen pharmazeutisch verträglichen Träger oder ein pharmazeutisch verträgliches Verdünnungsmittel.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 4, wobei die Zusammensetzung eine feste Dosierungsform ist.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Verbindung nach einem der Ansprüche 1-5 zur Verwendung bei der Therapie.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Verbindung nach einem der Ansprüche 1-5 zur Verwendung bei der Behandlung einer Entzündungserkrankung; wobei die Entzündungserkrankung bevorzugt ausgewählt ist aus Multipler Sklerose, Asthma, akutem Atemnotsyndrom, chronisch-obstruktiver Lungenerkrankung, chronischer Lungenentzündungserkrankung, Diabetes, entzündlicher Darmerkrankung, Osteoporose, Schuppenflechte, Transplantat-Wirt-Abstoßung, Arteriosklerose, multiplem Myelom, Schmerzen, myokardialer Ischämie und rheumatoider Arthritis.</claim-text></claim></claims><claims mxw-id="PCLM56979474" lang="EN" load-source="patent-office"><!-- EPO <DP n="54"> --><claim id="c-en-01-0001" num="0001"><claim-text>A compound of Formula I:
<chemistry id="chem0094" num="0094"><img id="ib0094" file="imgb0094.tif" wi="37" he="33" img-content="chem" img-format="tif"/></chemistry>
and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof, wherein:
<claim-text>R<sup>1</sup> is thiazol-5-yl substituted at the 2 position with C<sub>1-6</sub> alkyl amino; and</claim-text>
<claim-text>R<sup>2</sup> is phenyl optionally substituted with one or more substituents selected from the group consisting of halo, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl and hydroxy.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A compound according to claim 1, wherein R<sup>1</sup> is selected from the group consisting of:
<chemistry id="chem0095" num="0095"><img id="ib0095" file="imgb0095.tif" wi="112" he="35" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A compound according to any one of claims 1 or 2, wherein the compound is selected from the group consisting of<!-- EPO <DP n="55"> -->
<chemistry id="chem0096" num="0096"><img id="ib0096" file="imgb0096.tif" wi="125" he="46" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0097" num="0097"><img id="ib0097" file="imgb0097.tif" wi="88" he="45" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0098" num="0098"><img id="ib0098" file="imgb0098.tif" wi="88" he="46" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0099" num="0099"><img id="ib0099" file="imgb0099.tif" wi="90" he="46" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="56"> -->
<chemistry id="chem0100" num="0100"><img id="ib0100" file="imgb0100.tif" wi="94" he="48" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0101" num="0101"><img id="ib0101" file="imgb0101.tif" wi="94" he="48" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0102" num="0102"><img id="ib0102" file="imgb0102.tif" wi="96" he="48" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="57"> -->
<chemistry id="chem0103" num="0103"><img id="ib0103" file="imgb0103.tif" wi="108" he="56" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0104" num="0104"><img id="ib0104" file="imgb0104.tif" wi="47" he="46" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A pharmaceutical composition comprising at least one compound according to any one of claims 1-3 and a pharmaceutically-acceptable carrier or diluent.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>A pharmaceutical composition according to claim 4, wherein said composition is a solid dosage form.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A compound according to any one of claims 1-5 for use in therapy.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A compound of any one of claims 1-5 for use in the treatment of an inflammatory disorder; preferably wherein the inflammatory disorder is selected from the group consisting of multiple sclerosis, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, diabetes, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, multiple myeloma, pain, myocardial ischemia and rheumatoid arthritis.</claim-text></claim></claims><claims mxw-id="PCLM56979475" lang="FR" load-source="patent-office"><!-- EPO <DP n="61"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Composé de la Formule I:
<chemistry id="chem0116" num="0116"><img id="ib0116" file="imgb0116.tif" wi="38" he="36" img-content="chem" img-format="tif"/></chemistry>
et ses énantiomères, ses diastéréoisomères et ses sels pharmaceutiquement acceptables, dans lequel:
<claim-text>R<sup>1</sup> est un thiazol-5-yle substitué à la position 2 avec un C<sub>1-6</sub> alkylamino; et</claim-text>
<claim-text>R<sup>2</sup> est un phényle optionnellement substitué avec un ou plusieurs substituants choisis parmi un halo, un cyano, un C<sub>1-4</sub> alkyle et un hydroxy.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Composé selon la revendication 1, dans lequel R<sup>1</sup> est choisi parmi:
<chemistry id="chem0117" num="0117"><img id="ib0117" file="imgb0117.tif" wi="97" he="33" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Composé selon l'une quelconque des revendications 1 ou 2, où le composé est choisi parmi:
<chemistry id="chem0118" num="0118"><img id="ib0118" file="imgb0118.tif" wi="136" he="50" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0119" num="0119"><img id="ib0119" file="imgb0119.tif" wi="96" he="49" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="62"> -->
<chemistry id="chem0120" num="0120"><img id="ib0120" file="imgb0120.tif" wi="92" he="48" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0121" num="0121"><img id="ib0121" file="imgb0121.tif" wi="94" he="49" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0122" num="0122"><img id="ib0122" file="imgb0122.tif" wi="84" he="43" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0123" num="0123"><img id="ib0123" file="imgb0123.tif" wi="84" he="43" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0124" num="0124"><img id="ib0124" file="imgb0124.tif" wi="86" he="43" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="63"> -->
<chemistry id="chem0125" num="0125"><img id="ib0125" file="imgb0125.tif" wi="81" he="42" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0126" num="0126"><img id="ib0126" file="imgb0126.tif" wi="36" he="35" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Composition pharmaceutique comprenant au moins un composé selon l'une quelconque des revendications 1-3 et un support ou un diluant pharmaceutiquement acceptables.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Composition pharmaceutique selon la revendication 4, où ladite composition est une forme de dosage solide.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Composé selon l'une quelconque des revendications 1-5 pour une utilisation en thérapie.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Composé selon l'une quelconque des revendications 1-5 pour une utilisation dans le traitement d'un trouble inflammatoire; dans lequel de préférence le trouble inflammatoire est choisi parmi une sclérose en plaques, un asthme, un syndrome de détresse respiratoire aiguë, une maladie pulmonaire obstructive chronique, une maladie inflammatoire pulmonaire chronique, un diabète, une maladie intestinale inflammatoire, une ostéoporose, un psoriasis, un rejet de greffe contre hôte, une athérosclérose, un myélome multiple, une douleur, une ischémie myocardique et une polyarthrite rhumatoïde.</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
